TCL Archive Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent January 27, 2012Vol.35 No.1
TCL Archive FDA Didn’t Punish Duke for Failing To Seek Proper Regulatory Clearance for Three Trials January 27, 2012Vol.38 No.4
TCL Archive Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial January 27, 2012Vol.35 No.1
TCL Archive News Analysis by Keith Baggerly: Duke Trials Went On Despite FDA Statements January 27, 2012Vol.38 No.4
TCL Archive Matted Lymph Nodes Can Predict Survival Rate, Spread of Disease January 27, 2012Vol.35 No.1
TCL Archive Analysis Shows No Mortality Benefit From Regular PSA Screening January 27, 2012Vol.35 No.1
